2013 FEB 25 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Immunotech Laboratories, Inc. ( PINKSHEETS : IMMB) Announced $2M Funding approval from Bulgarian Immunotech Partnership Company (Immunotech BG) to begin clinical trials for HIV-AIDS advanced stages (see also Immunotech Laboratories, Inc.).
Immunotech's associate company in Bulgaria (Immunotech BG) confirmed the negotiations with two of the largest Bulgarian Hospitals for the start of Clinical Trials for the US Company's patented IPF-ITV and IPF-ITV Phases on 50 advanced stage patients.
Immunotech Director Bo Linton today commented "We believe that in both cases, the results will be very encouraging, as to this point we have already applied the medicine with volunteers and the results have been highly successful in Bulgaria, where the use of the vaccine labeled as an 'Experimental Drug' is permitted. The results of the Clinical Tests in Bulgaria should significantly help Fast-Track the FDA approval process in the USA, with the ultimate goal of the IPF medicines being available for treatment of HIV-AIDS patients in the USA."
Company President Harry Zhabilov stated, "The clinical trials in Bulgaria are scheduled to begin in March 2013 and will end in August 2013, which will give us the necessary results to receive approval for increased application for mass distribution for our IPF medicine."
Immunotech Laboratories BG will provide the necessary funding up to $2M for all of the above mentioned activities and contracts and all necessary related to the project, including in the USA.
Keywords for this news article include: Patents, Therapy, HIV/AIDS, Vaccines, Virology, RNA Viruses, Retroviridae, HIV Infections, Vertebrate Viruses, Primate Lentiviruses, Clinical Trial Research, Immunotech Laboratories Inc., Acquired Immunodeficiency Syndrome, Viral Sexually Transmitted Diseases.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC